Clinical Trial

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Evaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-26; most recent amendment 2026-05-25.
Status change: Recruiting → Active, Not Recruiting 2026-05-25
Status change: Not Yet Recruiting → Recruiting 2023-08-03
Trial Details
NCT Number NCT05890742
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions MSI-H
Enrollment 453 participants
Start Date 2023-05-25
Primary Completion 2028-04-15 (estimated)
Study Completion 2028-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-28